Dr James Spicer’s publications

‘Intracavitary T4 immunotherapy of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells’
Cancer Letters (2017) In press

‘Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors via TNF-α/MCP-1 signaling’
Cancer Research (2017) In press

‘A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours’
British Journal of Cancer (2017) In press

‘Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial’
JAMA Oncology (2017) 3:58-66

‘Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET)’
Journal of Clinical Oncology (2016) 35:402-411

‘A Phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumours’
Cancer Chemotherapy & Pharmacology (2016) 79:17-27

‘Development of downstream processing to minimise beta-glucan impurities in GMP-manufactured therapeutic antibodies’
Biotechnology Progress (2016) 32:1494-1502

‘The therapeutic targets and new directions for antibodies developed for ovarian cancer’
Bax H, Josephs D, Pellizzari G, Spicer J, Montes A & Karagiannis S
MAbs (2016) 8:1437-1455

‘Beta-glucan contamination of pharmaceutical products: How much should we accept?’
Cancer Immunology & Immunotherapy (2016) 65:1289-1301

‘IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin’
Scientific Reports (2016) 6:29736

‘IDEAL-CRT: A phase 1/2 trial of isotoxic dose-escalated radiation therapy and concurrent...’
chemotherapy in patients with stage II/III non-small cell lung cancer’


‘Targeting folate receptor alpha for cancer treatment’


‘The role of the HGF/Met axis in mesothelioma’
Thayaparan T, Spicer J & Mahler J

Biochemical Society Transactions (2016) 44:363-70

“‘I Can Breathe Again!’ Patients’ Self-Management Strategies for Episodic Breathlessness in Advanced Disease, Derived from Qualitative Interviews’

Journal of Pain & Symptom Management (2016) 52:228-34

‘HOX transcription factors are potential targets and markers in malignant mesothelioma’

BMC Cancer (2016) 16:85-95

‘Nedaplatin: a new platinum for squamous lung cancer?’
Wu Y & Spicer J

Lancet Oncology (2015) 16:1573-4

‘Epidemiology of lung cancer’
Repana D, Van Hemelrijck M & Spicer J

Springer (2015)

‘A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours’

European Journal of Cancer (2015) 51:2275-84

‘Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma’

OncoImmunology (2015) 4:11, e1032492

‘Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours’

Cancer Chemotherapy & Pharmacology (2015) 76:723-9

‘Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung’
Hall P, Spicer J & Popat S

Future Oncology (2015) 18:1-17

‘A randomized Phase 2 study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small-cell lung cancer (GALAXY-1)’


‘Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial’
‘Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors’


‘Phase I dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours’


First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer.


‘Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience’


‘Microdroplet digital PCR - detection and quantitation of biomarkers in archived tissue and serial plasma samples in patients with lung cancer’

Gao F, Pfeifer E, Farah H, Karampini E, Dua D, Kamal N, Cane P, Tobal K, Tariq Sethi T, Spicer J* & McCaughan F*

(*joint senior authors)


‘First-in-Human study of CH5132799, an oral Class I PI3K inhibitor, studying toxicity, pharmacokinetics and pharmacodynamics, in patients with metastatic cancer’


Clinical Cancer Research (2014) 20:5908-17

‘Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations’


Pharmacogenomics Journal (2014) 14:411-7

‘A Phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIIB/IV non-small-cell Lung cancer’


‘Effect of onartuzumab added to erlotinib on metastasis in patients with lung cancer’

Soultati A, Josephs D & Spicer J

Journal of Clinical Oncology (2014) 32:3781

‘The impact of socioeconomic status on access to cancer clinical trials’

Sharrocks K, Spicer J, Camidge R & Papa S

British Journal of Cancer (2014) 111:1684-7

‘Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma’

Molecular Cancer Therapeutics (2014) 13:2769-83

‘EGFR-mutated lung cancer in Li-Fraumeni syndrome’
Michalarea V, Calcasola M, Cane P, Tobal K, Izatt L, Spicer J

Lung Cancer (2014) 85:485-487

‘Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency’

MAbs (2014) 6:509-22

‘IgE immunotherapy: A novel concept with promise for the treatment of cancer’
Josephs D, Spicer J, Karagiannis P, Gould H & Karagiannis S

MAbs (2014) 6:54-72


‘Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors’

Cancer Chemotherapy & Pharmacology (2013) 72:1213-1222

‘Design of a Phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted CAR T cells in locally advanced or recurrent head and neck cancer’


‘Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication’
Bille A, Chicklore S, Okior L, Cook GJ, Spicer J, Landau D & Lang-Lazdunski L

Nuclear Medicine Communications (2013) 34:1075-83

‘Epidemiological associations of allergy, IgE and cancer’
Josephs D, Spicer J, Corrigan C, Gould H & Karagiannis S

Clinical & Experimental Allergy (2013) 43:1110-23

‘Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy’

Journal of Thoracic Oncology (2013) 8:783-7

‘Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring’
Josephs D, Fisher D, Spicer J & Flanagan R

Therapeutic Drug Monitoring (2013) 35:562-87

‘Episodes of breathlessness: Types and patterns - a qualitative study exploring experiences of patients with advanced diseases’
Simon S, Higginson I, Benalia H, Gysels M, Murtagh F, Spicer J & Bausewein C.

Palliative Medicine (2013) 27:524-32

‘Drugs for cancer’

Spicer J & De Bono J


‘IgG4 subclass antibodies impair antitumor immunity in melanoma’

Reply to Surbone A et al. ‘Culture matters as well’

**Spicer J**, Moller H & Papa S

*Journal of Clinical Oncology* (2013) 31:2833

‘Effect of patient socio-economic status on access to early phase cancer trials’

Mohd Noor A, Sarker D, Vizor S, McLennan B, Hunter S, Suder S, Moller H, **Spicer J*** & Papa S

(*corresponding author)


‘First in-human phase I trial of two schedules of OSI 930, a novel multikinase inhibitor, incorporating translational proof of mechanism studies’


‘Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours’


*Cancer Chemotherapy and Pharmacology* (2013) 71:543-9

‘Episodic and continuous breathlessness: a new categorization of breathlessness’

Simon S, Higginson I, Benalia H, Gysels M, Murtagh F, **Spicer J** & Bausewein C


‘EGFR inhibition and more: a new generation growing up’

Enting D & **Spicer J**


‘An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry’

Couchman L, Birch M, Ireland R, Corrigan A, Wickramasinghe S, Josephs D, **Spicer J** & Flanagan R

*Analytical & Bioanalytical Chemistry* (2012) 403: 1685-95

‘Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma’

Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, Landau D, Steele J, **Spicer J**

*Journal of Thoracic Oncology* (2012) 7: 737-43

‘Routine EGFR and KRAS mutation analysis using COLD-PCR in non-small cell lung cancer’


‘Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals’

Bille A, Belcher E, Raubenheimer H, Landau D, Cane P, **Spicer J** & Lang-Lazdunski L


‘EGFR tyrosine kinase inhibitors in the treatment of EGFR mutant NSCLC metastatic to the brain’

Jamal-Hanjani M & **Spicer J**


‘Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application’


*Cancer Immunology & Immunotherapy* (2012) 61: 1547-1564

‘Trends in incidence of small cell lung cancer and all lung cancer’

Riaz SP, Lüchtenborg M, Coupland VH, **Spicer J**, Peake MD, Møller H

*Lung Cancer* (2012) 75: 280-4

‘A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma’


‘Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma’

Lang-Lazdunski L, Bille A, Belcher E, Cane P, Landau L, Steele J, Taylor H, & Spicer J

*Journal of Thoracic Oncology* (2011) 6: 1746-52

‘Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study’


‘Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.’


‘Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity’


*Clinical & Experimental Allergy* (2011) 41: 1400-1413

‘The challenges of integrating molecular imaging into the optimization of cancer therapy’


*Integrative Biology* (2011) 3: 603-31

‘Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies’


*PLoS ONE* (2011) 6: e19330

‘Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma’


‘A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics’


‘A phase 1 study of intravenous reovirus and docetaxel in patients with advanced cancer’


‘The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study’


‘Phase I trial of the irreversible ErbB1 (EGFR) and ErbB2 (HER2) kinase inhibitor BIBW 2992 in patients with advanced solid tumours’


‘EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992’
Spicer J & Rudman S
Targeted Oncology (2010) 5: 245-55

‘Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.’
Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L

‘Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4’
Wilkie S, Burbridge S, Chiapero-Stanke L, Pereira A, Cleary S, van der Stegen S, Spicer J, Davies D & Maher J


‘Unilateral diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and multiple carcinoids treated with surgical resection’
Irshad S, McLean E, Rankin S, Barrington S, Santis G, Spicer J & Lang-Lazdunski L

‘Molecular imaging in clinical trials’
Josephs D, Spicer J & O’Doherty M
Targeted Oncology (2009) 4: 151-5

‘The Mesothelioma and Radical Surgery randomized controlled trial: the MARS feasibility study’

‘A first-in-man phase 1 and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors’
Clinical Cancer Research (2009) 15:4978-85

‘Second generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer’
Mukherji D & Spicer J
Expert Opinion on Investigational Drugs (2009) 18:293-301

‘Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/Neu-positive tumour cells’
Cancer Immunology & Immunotherapy (2008) 58:915-30

‘Targeted therapies in non-small cell lung cancer’
Kyle F and Spicer J
Cancer Imaging (2008) 8:199-205

‘A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell Lung cancer (NSCLC): SCRATCH study’

‘Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study’
Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V & Pandha H
Journal of Urology (2007) 177:2136-2140

‘Pharmacogenomics of non-small cell lung cancer’
Spicer J, Futreal A and De Bono J
‘Targeting novel and established therapies for non-small cell lung cancer’

Spicer J, Chowdhury S and Harper P
‘Renewed hope in the treatment of renal cell carcinoma’
Chowdhury S, Spicer J and Harper P
‘Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibitor therapy’
Spicer J and Ellis P
‘Hypertension and targeted therapy’: Parts I & II
Chowdhury S, Spicer J and Harper P
Targeted Oncology (2006) 1:104-8 & 175-8
‘Stable disease for three years in metastatic malignant melanoma treated with the heat shock protein inhibitor 17-AAG’
Spicer J, Banerji U, Hanwell J and Judson I
Targeted Oncology (2006) 1:54-55
‘Bronchial carcinoid’
Chowdhury S, Cane P, Spicer J and Harper P
‘Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer’
Spicer J, Plunkett T, Chan S, Kendal A, Bolunwu N, and Pandha H
Prostate Cancer & Prostatic Diseases (2005) 8:364-8
‘Nimotuzumab – technology evaluation’
Spicer J
Current Opinion in Molecular Therapeutics (2005) 7:182-191
‘Adjuvant trastuzumab for HER2-positive breast cancer’
Spicer J, Harries M and Ellis P
‘Targeted therapies in non-small cell lung cancer’
Spicer J and Harper P
‘Combination therapy versus single agent chemotherapy in non-small cell lung cancer’
Cheong K, Spicer J, Chowdhury S and Harper P
‘Updates in the management of female germ cell tumours’
Spicer J, Cheong K and Harper P
MIMS Advances (2005) Issue 6
‘The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressors’
‘Cellular immunotherapy for cancer: current concepts and clinical perspectives: Monitoring immune responses and clinical trials: Parts I & II’
Spicer J, Quatan N, Plunkett T and Pandha H
‘LKB1 kinase: master and commander of metabolism and polarity’
Spicer J & Ashworth A
‘Petuzumab – technology evaluation’
Spicer J
Current Opinion in Molecular Therapeutics (2004) 6: 337-343
‘Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin’s lymphoma’
‘Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers Syndrome kinase LKB1’

Spicer J, Rayter S, Young N, Elliott R, Ashworth A and Smith D
Oncogene (2003) 22; 4752-6
‘Malignant melanoma’

Spicer J & Gore ME
‘LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1’

Smith DP, Rayter SI, Niederlander C, Spicer J, Jones CM, Ashworth A
Human Molecular Genetics (2001) 10; 2869-77

‘The Peutz-Jeghers gene Lkb1 encodes a nuclear protein kinase’

Smith DP, Spicer J, Smith A, Swift S & Ashworth A
Human Molecular Genetics (1999) 8; 1479-85

‘Amplification and over-expression of the MDM2 gene in human soft tissue sarcomas’

Sarcoma (1997) 1;17-22

‘The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target’
Picksley SM, Spicer J, Barnes DM & Lane DP
Acta Oncologica (1996) 35; 429-434

‘Co-expression of p53 and MDM protein in both benign and malignant tissues in two cancer prone families’
Barnes DM, Spicer J, Picksley SM, Lane DP, Bobrow LG, Hill DE, Hodgson S & Mohammed S
European Journal of Cancer (1994) 30A; S20

PRESENTATIONS & POSTERS AT NATIONAL & INTERNATIONAL MEETINGS

San Antonio Breast Cancer Symposium, December 2016
‘A phase I/II study of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer’


ESMO Annual Meeting, Copenhagen, October 2016:
‘An investigator initiated study combining the dual mTORC1/2 inhibitor Vistusertib (AZD2014) with weekly paclitaxel in high grade serous ovarian cancer’

ASCO Annual Meeting, Chicago, June 2016:
‘Pharmacokinetic effects and safety of olaparib in combination with tamoxifen, anastrozole, or letrozole: Phase I study’


‘A Phase 1 study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients with advanced solid tumors’


British Thoracic Oncology Group Meeting, Dublin, January 2016:
‘UK prescribers’ attitudes to epidermal growth factor receptor mutation testing in advanced non-small cell lung cancers and its impact on treatment decisions: UK findings from a global survey’

Spicer J, Tischer B & Peters M

San Antonio Breast Cancer Symposium, December 2015:
‘Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases’
JAMES SPICER


National Cancer Research Institute Annual Meeting, Liverpool, November 2015:
‘Evidence for safety and efficacy of a tumour-specific IgE antibody therapeutic candidate for ovarian cancer immunotherapy in the presence of soluble circulating tumour-associated antigen’

ECCO Meeting, Vienna, September 2015:
‘Intratumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces infiltration of CD8 effector T-cells and regression in some injected tumours’

IASLC World Conference on Lung Cancer, Denver, September 2015:
‘Tumour Molecular profiling and quantitative detection of circulating biomarkers in patients with NSCLC’

ASCO Annual Meeting, Chicago, June 2015:
‘Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases’
‘Phase 1 study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer’

European Lung Cancer Conference, Geneva, April 2015:
‘EGFR mutation testing and oncologist treatment choice in advanced NSCLC’
Spicer J, Tischer B & Peters M

British Thoracic Oncology Group Meeting, Dublin, January 2015:
‘Tumour molecular profiling and quantitative detection of circulating biomarkers in patients with lung cancer’
Karampini E, Farah H, Kamal N, Tobal K, Cane P, Moorhead J, Pomplun S, King J, Sethi T, McCaughan F & Spicer J

National Cancer Research Institute Annual Meeting, Liverpool, November 2014
‘Identification of novel pharmacogenetic markers of platinum-induced toxicity using exome chip technology’

‘Monocyte activation and recruitment by IgE therapy against cancer’

‘Immunotherapy of mesothelioma using Met-specific T-cells’
‘The use of microdroplet digital PCR in the detection of mutational events in cell-free tumour DNA in patients with lung cancer’
Gao F, Farah H, Pfeifer E, Dua D, Kamal E, Tobal K, Cane P, Spicer J & McCaughan F

ESMO Annual Meeting, Madrid, September 2014:
‘ET: A randomized, multicenter, phase III trial of platinum versus nonplatinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer (NSCLC)’

ASCO Annual Meeting, Chicago, June 2014:
‘GALAXY-2 trial: a randomized phase 3 study of ganetespib in combination with docetaxel vs
docetaxel alone in patients with advanced lung adenocarcinoma'

British Thoracic Oncology Group Meeting, Dublin, January 2014:
'Microdroplet digital PCR in detecting mutational events in cell-free DNA in patients with lung cancer – a pilot study'
Gao G, Dua D, Pfeifer E, Farah H, Tobal K, Canep N, Spicer J & McCaughan F

'Characterising the use and impact of bisphosphonates in patients with bone metastases from non-small cell lung cancer; a single centre experience’
Beddowes E, Hatiqsaglu E, Montes A, Spicer J, Moller H & Lal R

'Outcome in metastatic NSCLC without EGFR and KRAS mutation treated with second line erlotinib’
Dua D, Montes A, Warner M, Spicer J & Lal R

'A retrospective analysis of patients with advanced EGFR mutated lung cancer treated with either first line erlotinib or gefitinib’
Thillai K, Soultati, Montes A, Karapanagiotou E, Spicer J & Lal R

'Lung cancer presenting with symptomatic bone metastases: Are we doing enough?’
Thillai K, Soultati S, Lawrence H, Spicer J, Lal R & Montes A

'The prevalence of hyponatraemia amongst patients with newly diagnosed thoracic malignancies’

'Immunotherapy of malignant pleural mesothelioma using MET specific T-cells’
Thayaparan T, Van der Stegen S, Parente Pereira A, Petrovic R, Spicer J & Maher J

San Antonio Breast Cancer Symposium, December 2013
'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients with heavily-pretreated HER2-positive metastatic breast cancer’

Association for Molecular Pathology Annual Meeting, Phoenix, November 2013
‘Anglo-American Ring Trial unveils pre-PCR error and false-negative results in BRAF and EGFR cancer diagnostics’

AACR-NCI-EORTC Molecular Targets Meeting, Boston, October 2013:
‘Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors’

European Cancer Congress, Vienna, September 2013:
‘A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours’

ASCO Annual Meeting, Chicago, June 2013:
‘Correlative biomarker analysis of sequential tumor biopsies in a ph I mode of action study in neo-adjuvant Head and Neck Squamous Cell Carcinoma patients treated with RG7160 (GA201), a novel dual-acting, monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity, with cetuximab as reference’

‘Antibiotic prescribing in primary care for end-of-life cancer patients’
Gao W, Spicer J & Irene Higginson I

‘A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)’
JAMES SPICER


7th International Meeting on Oncolytic Viruses, Quebec, June 2013:
‘Getting oncolytic viruses past antibodies: A Phase I study to evaluate cyclophosphamide as a modulator of immune response to RT3D (reovirus type 3 Dearing)’

European Multidisciplinary Conference in Thoracic Oncology, Lugano, May 2013:
‘A phase II/II trial of concurrent chemo-radiation with dose-escalated radiotherapy in patients with stage II or III non-small cell lung’

Targeted Anticancer Therapies, Paris, March 2013:
‘Final results of Phase 1 study of the oral Class I PI3K inhibitor CH5132799 in patients with advanced solid tumours’

British Thoracic Oncology Group Meeting, Dublin, January 2013:
‘Testing for association between TPMT, COMT and NOX3 variants and the onset of ototoxicity in lung cancer patients treated with platinum chemotherapy’

‘Acquired resistance to EGFR inhibition: evolution from adenocarcinoma to small cell lung cancer’
Moss C, Cane P, Molean E, Santis G, Tobal K & Spicer J

‘Treating non-small cell lung cancer with erlotinib: the nurse-led clinic experience’

ESMO Annual Meeting, Vienna, September 2012:
‘A phase I study of daily afatinib, an irreversible ErbB family blocker, combined with weekly paclitaxel and 2-weekly bevacizumab in patients with advanced solid tumours’

‘The impact of patient socio-economic status on access to early phase cancer trials’

‘Phase I/II trial of abiraterone acetate in oestrogen receptor- or androgen receptor-positive metastatic breast cancer’

‘Final results of a phase 2, open-label study of ramucirumab (IMC-1121B), an IgG1 mAb targeting VEGFR-2, with paclitaxel and carboplatin as first-line therapy in patients with stage IIIb/IV non-small cell lung cancer’

ASCO Annual Meeting, Chicago, June 2012:
‘Efficacy and biomarker findings of RG7160 (GA201) a novel glycoengineered monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity, in combination with 1st line cisplatin and pemetrexed in metastatic non-squamous NSCLC’

‘A phase 1 study of S-222611, an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumours’
'Exploratory pharmacodynamics trial to investigate the mechanism of action of RG7160 (GA201), a novel dual-acting, monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity (ADCC), compared with cetuximab in neoadjuvant head and neck squamous cell carcinoma'


'A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors'


European Lung Cancer Conference, Geneva, April 2012:

'A phase 2 study of sorafenib after first line platinum containing combination chemotherapy in malignant mesothelioma'

AACR Annual Meeting, Chicago, April 2012:

'Antibodies of the IgG and IgE classes against the melanoma-associated antigen HMW-MAA: Investigating a new therapeutic approach'


ASCO Gastrointestinal Cancers Symposium, San Francisco, January 2012:

'Is there a clinical benefit in testing for UGT1A1*28 prior to irinotecan therapy?'


AACR-NCI-EORTC Molecular Targets Meeting, San Francisco, November 2011:

'First-in-patient Study of PF-05212384, a Small-molecule Intravenous Dual Inhibitor of PI3K and mTOR 1/2 in Patients with Advanced Cancer: Update on Safety, Efficacy, and Pharmacology'


Congress of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Stuttgart, October 2011:

'TurboFlow™ technology for the therapeutic drug monitoring of tyrosine kinase inhibitors'

Miles S, Couchman L, Josephs D, Spicer J, Flanagan RJ

ASCO Annual Meeting, Chicago, June 2011:

'Phase I study of abiraterone acetate in patients with estrogen- or androgen-receptor positive advanced breast carcinoma resistant to standard endocrine therapies'


NCIN & UKACR Conference, London, June 2011:

'Trends in incidence of small cell lung cancer and all lung cancer'

Riaz S, Lüchtenborg M, Coupland V, Spicer J, Peake M & Moller M

Association for Clinical Chemistry FOCUS meeting, Harrogate, 2011

'TurboFlow™ Technology for High-Throughput Therapeutic Drug Monitoring: Tyrosine Kinase Inhibitors'

Miles S, Couchman L, Moniz C, Spicer J & Flanagan R

Society of Nuclear Medicine Annual Meeting, San Antonio, April 2011:

'Development of an imaging tool for evaluating a novel IgE therapy'


British Thoracic Oncology Group Meeting, Dublin, January 2011:

'Prevalence of EGFR and K-RAS mutation status in clinical practice – relationship to patient characteristics'
JAMES SPICER

Simpson T, Pennycuick A, Crawley D, Tobal K, Cane P, Santis G & Spicer J

‘Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and adjuvant chemotherapy in patients with malignant pleural mesothelioma’
Lang-Lazdunski, Bille E, Bechier E, Landau D, Steele J, Taylor H & Spicer J

NCRI Annual Meeting, Liverpool, November 2010:
‘Effect of patient factors & referrer attitudes on patient recruitment to phase 1 oncology trials’

AACR-NCI-EORTC Molecular Targets Meeting, Berlin, November 2010:
‘First-in-human study of PF-05212384, a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics’

‘Preliminary report of efficacy of abiraterone acetate in patients with estrogen (ER) or androgen receptor (AR) positive, advanced breast carcinoma resistant to standard endocrine therapies’

ASCO Annual Meeting, Chicago, June 2010:
‘A phase 2 study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18FGD-PET’

‘A phase 2 study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme’

‘A phase 2, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIb/IV non-small cell lung cancer’

AACR Annual Meeting, Washington DC, April 2010:
‘Pre-clinical development of adoptive-T-cell therapy for prostate cancer incorporating a novel chimeric cytokine receptor’
Burbridge S, Wilkie S, Davies M, Chiapero-Stanke L, Maher M & Spicer J

British Society of Dermatology Annual Meeting, Edinburgh, April 2010:
‘IgE Immunotherapy of solid tumours: a novel nodel targeting folate receptor alpha-positive carcinomas with MOv18 IgE’

British Thoracic Oncology Group Meeting, Dublin, January 2010:
‘Early rehabilitation following lung resection for cancer - a pilot study’
Paterson S, Hart N, Cage C, Spicer J

AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, Boston, November 2009:
‘Extended follow-up from a phase 1 study of AS1409, a novel antibody-cytokine fusion protein, suggests efficacy in malignant melanoma’
Rudman S, Jameson M, Savage P, Jodrell D, Erlandsson F, Jones D, Keage M, Spicer J

‘Development of adoptive-T-cell therapy for prostate cancer incorporating a novel chimeric cytokine receptor.’
Burbridge S, Wilkie S, Davies D, Chiapero-Stanke L, Maher J, Spicer J

World Conference on Lung Cancer, San Francisco, August 2009:
‘Activity of BIBW 2992, an oral irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer’

‘Mesothelioma and radical surgery trial (MARS): the feasibility study process’

ASCO Annual Meeting, Orlando, Florida, June 2009:
‘A phase I study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma’


‘Results of a phase I study to evaluate the feasibility, safety, and biological effects of intravenous administration of wild-type reovirus with docetaxel to patients with advanced malignancies’


‘A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel’


British Thoracic Oncology Group Meeting, Dublin, January 2009:
‘Treatment-associated deaths and mortality following chemotherapy for non-small cell lung cancer’

Soffin E, Alam S, Hogan V, Rudman S & Spicer J

NCRI Annual Meeting, Birmingham, October 2008:
‘IgE antibody immunotherapy of solid tumours: A novel model targeting folate receptor with MOv18 IgE’

Rudman S, Karagiannis S, Hunt J, Gould H & Spicer J

ESMO, Stockholm, September 2008:
‘A phase I study of daily BIBW 2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel’


EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, San Francisco, October 2007:
‘An exploration of the ability of DCE-CT scans to evaluate blood flow in an open, pharmacokinetic (PK) and mass balance study of 14[C]-cediranib.’


12th IASLC World Conference on Lung Cancer, Seoul, September 2007:
‘Activity of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer with mutated EGFR.’


ASCO Annual Meeting, Chicago, Illinois, June 2007:
‘Final results of a phase I study of oncolytic reovirus administered intravenously to patients with advanced cancer’


‘A phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumours.’

Shaw H, Molife R, Spicer J, Karavisilis V, Marriott C, Ong T, Tate L, Brendel E, Christensen O, & De Bono J

‘An open, pharmacokinetic (PK) and mass balance study of 14C-AZD2171, incorporating DCE-CT evaluations.’

Reid A, Tang A, Spicer J, Gallerani E, Mears D, Settatree S, Yap T, Puchalski T, Harrison M & De Bono J

‘First in-human phase 1 trial of a novel amino-peptidase inhibitor, CHR-2797.’


EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, November 2006:
‘A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer’


‘A phase I trial incorporating the pharmacodynamic study of circulating tumour cells of CP-751,871,
a monoclonal antibody against the insulin-like growth factor 1 receptor, in combination with
docetaxel in patients with advanced cancer’
Bono J

ASCO Annual Meeting, Atlanta, Georgia, June 2006:
‘Phase I pharmacokinetic and pharmacodynamic evaluation of a small molecule inhibitor of Poly
ADP-Ribose Polymerase (PARP), KU-0059436 in patients with advanced tumours’

‘A phase I study of Reolysin given intravenously to patients with advanced malignancies’
Bono J

Phase I trial involving the pharmacodynamic study of circulating tumour cells, of CP-751,871, a
monoclonal antibody against the insulin-like growth factor 1 receptor, with docetaxel in patients with
advanced cancer

‘A phase I dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with
advanced solid tumours’
Bono J

ASCO Prostate Cancer Symposium, Orlando, Florida, February 2005:
‘Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer’
Spicer J, Plunkett T, Chan S, Kendal A, Bolunwu N & Pandha H

ASCO Annual Meeting, Orlando, Florida, May 2005:
‘A single centre retrospective review of oral cyclophosphamide in hormone-refractory prostate
cancer.
Cheong K, Chrystal K, Spicer J, & Harper P

McElwain Prize presentation at BCRM, Manchester, 2004:
‘A new molecular target in colorectal cancer signalling: the LKB1 tumour suppressor gene and Wnt
signalling’
Spicer J

Signaling systems: chemistry biology & pathology, Steamboat Springs, Colorado, 2001:
‘Anchoring of Peutz-Jeghers syndrome kinase LKB1 by the novel protein LIP1 allows interaction
with cytoplasmic signaling components’
Spicer J, Smith D & Ashworth A

6th EORTC Breast Cancer Working Conference, Amsterdam, 1994:
‘Co-expression of p53 and MDM protein in both benign and malignant tissues in two cancer prone
families’
Spicer J & Barnes D